Clinical Trial

ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
ACTEMRA (tocilizumab) is an IL-6 receptor antagonist used for the treatment of adult Rheumatoid Arthritis as well as Polyarticular (PJIA) and Systemic (SJIA) Juvenile Idiopathic Arthritis. In this Phase II, the drug will be used to treat pediatric patients diagnosed with recurrent Adamantinomatous Craniopharyngioma including patients who have undergone surgery and/or radiation therapy.
Protocol Amendment History 1 change
notable Enrollment reduced: 38 -> 30 participants 2026-04-24
Trial Details
NCT Number NCT05233397
Lead Sponsor Nationwide Children's Hospital
Collaborators: Children's Hospital Colorado
Conditions Adamantinomatous Craniopharyngioma, Recurrent Adamantinomatous Craniopharyngioma
Enrollment 30 participants
Start Date 2022-12-16
Primary Completion 2027-12 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-23